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ABSTRACT
Objectives To assess the prevalence and risk factors of 
overweight and obesity among type 2 diabetes mellitus 
(T2DM) patients in Uganda.
Design Retrospective chart review.
Setting This study was conducted in the outpatient’s 
T2DM clinic in St. Francis Hospital—Nsambya, Uganda 
between March and May 2017.
Participants Type 2 diabetes patients registered in the 
diabetes clinic between July 2003 and September 2016.
Outcome measures Overweight and obesity defined as 
body mass index (kg/m2) of 25.0–29.9 and obesity as 30.0 
or higher.
Results Of 1275 T2DM patients, the median age was 
54 (IQR: 44–65) years, 770 (60.40%) were females, 887 
(69.6%) had hypertension, 385 (28%) had controlled 
glycaemia, 349 (27%) were obese, while 455 (36%) 
were overweight. Overweight/obesity were lower among 
men (OR: 0.45, 95% CI: 0.340 to 0.593, p≤0.001) and 
among patients aged ≥65 years (OR: 0.52, 95% CI: 0.350 
to 0.770, p=0.001); patients who rarely ate fruits and 
vegetables (OR: 0.66, 95% CI: 0.475 to 0.921, p=0.014) 
but higher among patients of middle (OR: 1.83, 95% CI: 
1.320 to 2.550, p≤0.001) and upper (OR: 2.10, 95% CI: 
1.450 to 2.990, p≤0.001) socioeconomic status; on dual 
therapy (OR: 2.17, 95% CI: 1.024 to 4.604, p=0.043); with 
peripheral neuropathy (OR: 1.40, 95% CI: 1.039 to 1.834, 
p=0.026) and hypertension (OR: 1.70, 95% CI: 1.264 to 
2.293, p≤0.001).
Conclusions Overweight and obesity are high among 
T2DM patients in this population and may contribute 
significantly to poor outcomes of T2DM. Therefore, 
strategies to address this problem are urgently needed.
INTRODUCTION
Overweight, defined as a body mass index 
(BMI) of 25.0–29.9 kg/m2, and obesity as 
BMI 30.0 kg/m2 or above, represent progres-
sive buildup of adipose tissue to levels that 
damage the physical and psychosocial health 
and well- being of an individual. Globally, 
the prevalence of obesity doubled in 73 
countries between 1980 and 2015, and in 
2015 about 604 million adults were obese.1 
Overweight and obesity are a major threat 
to health, causing morbidity in over 2 billion 
people worldwide and accounting for at least 
2.8 million (fifth leading cause) of deaths per 
year in adults.2 Approximately, 44% of the 
burden of diabetes mellitus, 23% of the isch-
aemic heart disease and up to 41% of certain 
cancer are attributable to overweight and 
obesity.
The correlation between obesity and 
type 2 diabetes mellitus (T2DM) has been 
constantly proven and reproducibly observed 
in a wide range of studies across different 
populations.3–5 Obesity is the most important 
risk factor for T2DM and has been postulated 
to be the major contributor to the current 
Strengths and limitations of this study
 ► This study is one of the first studies to report on 
the prevalence and factors associated with over-
weight and obesity among type 2 diabetes patients 
in Uganda.
 ► The use of patients’ routine care data for this review 
has provided a large sample size which would not 
have been possible otherwise.
 ► The method used by the health facility to classify 
socioeconomic status and residence was not stan-
dardised and could have changed over the years.
 ► This study was conducted in outpatient diabetes 
clinics in a private not for profit facility and did not 
include those from public health facilities and the 
results may not be generalisable to the general pop-
ulation in Uganda.
 ► This operational programme data were not designed 
for research purposes, were not validated, had no 
quality checks done for completeness and plausi-
bility and only limited number of variables were 
captured.
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epidemics of T2DM. Moreover, the presence of obesity 
among type 2 diabetes patients increases the risk of 
mortality from cardiovascular disease.4 6 A meta- analysis of 
five longitudinal cohort studies demonstrated that over-
weight or obese diabetes patients had a twofold greater 
relative risk of mortality than normal- weight patients.7 
Obesity also promotes insulin resistance and metabolic 
syndrome whose other components besides hypergly-
caemic are hypertension, dyslipidaemia, proinflamma-
tory and prothrombotic state.8 Overweight and obesity 
also increases the likelihoods of suboptimal glycaemic 
control making it difficult to achieve glycaemic targets.9 
As a result, the American Diabetes Association recom-
mends and has developed guidelines for weight manage-
ment in diabetic patients with overweight or obesity.10 11
Sub- Saharan Africa is experiencing a rapidly increasing 
burden of obesity, diabetes and other non- communicable 
diseases.12 13 However, there are limited reliable data on 
the prevalence of obesity and how this contributes to the 
risk of T2DM in the region. A few studies indicate that 
overweight and obesity affects up to half of the type 2 
diabetes patients, with prevalence varying according to 
age and setting; 85% in Tanzania14 and 27.4%–83% in 
Nigeria.15 16
In Uganda, nationwide health and demographic 
surveys showed a significant rise in the prevalence of over-
weight (9.77% vs 16.21%) and obesity (1.99% vs 6.21%) 
in the general population between 1995 and 2016, 
respectively.17 However, the prevalence of overweight and 
obesity among type 2 diabetes patient in Uganda is not 
known. This study was therefore undertaken to docu-
ment the prevalence of overweight and obesity among 
type 2 diabetes patients, and the associated factors.
METHODS
Study design, setting and population
This descriptive retrospective study reviewed 2518 
medical records of adult patients with T2DM who had 
registered at St. Francis Hospital Nsambya in Kampala- 
Uganda. The hospital is a private not for profit health 
facility which conducts a weekly diabetes mellitus clinic 
managing an average of 60 patients on every clinic day. 
During each clinic visit, trained nurses offer diabetes 
mellitus health education, biophysical and fasting blood 
glucose measurements are done prior to being reviewed 
by the doctors.18 The study population consisted of T2DM 
patients registered at the clinic between July 2003 and 
September 2016. Patients clinic records (paper- based) 
were reviewed by a trained medical doctor, clinical officer 
and registered nurses between March and May 2017.
Sample size and sampling procedure
To achieve a desired level of precision and a higher power 
all the 2518 patients registered in the T2DM clinic were 
considered. Consecutive convenience sampling method 
was used because of a substantial number of missing files 
and missing information. Patients whose records could 
not be located, those with missing information including 
height and weight, type 1 diabetes mellitus or with gesta-
tional diabetes were excluded.
Data source and collection
The data for this research were secondary data collected 
routinely in the hospital for patients’ clinical monitoring 
and evaluation purposes. Data were abstracted from the 
hospital records and entered into a Microsoft Excel 2010 
database (Microsoft Corp., Redmond, WA), checked 
for consistencies, outliers and completeness and then 
exported to STATA V.15 (Stata Corp, College Station, 
TX, USA) for further data cleaning, management and 
analysis. Data collected for this review included socio-
demographics, medical history, glycaemic levels, medi-
cation use, complications of diabetes and biophysical 
measurements.
The primary outcome variable was overweight taken as 
a BMI of 25.0–29.9 kg/m2, and obesity as BMI 30.0 kg/m2 
or above.
Clinical description of predictor and outcome variables
BMI was calculated as weight in kilograms divided by the 
square of height in metres (kg/m2). We used the WHO 
BMI (in kg/m2) definition as follows: normal weight: 
18.0–24.9, overweight: 25.0–29.9 and obesity: 30.0 or 
higher.19
Hypertension was defined as systolic blood pressure 
≥140 mm Hg and/or diastolic pressure of ≥90 mm Hg or 
on antihypertensive medication or a recorded diagnosis 
of hypertension.
Optimal glycaemic control was defined as preprandial 
glucose 4.4–7.2 mmol/L. Fasting glucose reading of 
>7.2 mmol/L was considered as uncontrolled glycaemia 
among diabetes patients. Glucose reading was recorded 
as an average of the last three measurements on three 
separate clinic visits.
Diabetes mellitus treatment options: life style alone was 
defined as non- pharmacological treatment involving 
changes in diet and increased exercise; monotherapy 
as use of metformin only or any other single oral hypo-
glycemic; dual therapy as a combination of metformin 
and another oral hypoglycemic agent or metformin and 
insulin; triple therapy as a combination of metformin and 
two other oral hypoglycemic agents or metformin and 
another oral hypoglycemic plus insulin and combina-
tion injection therapy was defined as the use of different 
insulin regimens.
Residence: the host hospital’s definitions were used; 
urban was defined as living within 1 km of a town council; 
peri- urban as living within 1 km of a shop selling soft 
drinks and rural as living more than 1 km of a shop selling 
soft drinks.
Socioeconomic status (SES) was defined based on house-
hold assets. Upper SES defined as living in a house with 
electricity or solar power supply, piped water, flushing 
toilet and kitchen inside; middle SES as living in a house 
with at least one but not all the utilities above; lower SES 
3Tino S, et al. BMJ Open 2020;10:e039258. doi:10.1136/bmjopen-2020-039258
Open access
as living in a house without the above and not mud or 
wattle and not grass hatched; poor SES as living in mud 
and wattle grass hatched house and none of the amenities 
above.
Potential confounders were age, sex, SES and residence.
Statistical analysis
Statistical analysis was performed using STATA V.15 
(Stata Corp, College Station, TX, USA). All variables were 
checked for missing data and inconsistencies. Distribu-
tion of the data using summary measures and graphical 
displays was examined to identify outliers and verified 
against source documentation. The patients’ characteris-
tics were summarised using means±SD or medians and 
percentages. The Kruskal- Wallis equality of proportions 
test was used to assess the association between participants 
age and the various BMI categories. Categorical variables 
were reported as numbers and percentages. Chi- square 
test (χ2) was used to determine differences in prevalence 
of overweight and obesity and baseline characteristics of 
patients. Based on the χ2 test and Kruskal- Wallis equality 
of proportions test, variables that were significantly associ-
ated (p<0.05) with the different BMI categories were used 
in the subsequent analysis.
Bivariate logistic regression analysis was used to deter-
mine whether patients’ characteristics including age, 
sex, education, area of residence, hypertension, diabetes 
complications, diabetes treatment, smoking, socioeco-
nomic status and participants adherence to study visits 
(lost to follow- up) were associated with overweight/
obesity. Based on the results obtained from the bivariate 
logistic regression models, variables that were found to 
have an independent association, that is, gender/sex, 
education, area of residence, hypertension, fruit/vege-
table intake, smoking, socioeconomic status, diabetes 
complications and participant’s adherence to study 
visits with the outcome in addition to age and diabetes 
treatment were added to the final multivariate logistic 
regression model. Age and diabetes treatment were 
added to this model based a priori knowledge of a known 
confounding effect of these variables with the outcome. 
From the unadjusted and adjusted models, p- values, OR 
and corresponding 95% CIs were reported.
Results
Patients’ characteristics and prevalence of overweight and obesity 
Between July 2003 and September 2016, a total of 2518 
diabetes mellitus patients were registered in the diabetes 
clinic of St. Francis Hospital Nsambya in Kampala, 
Uganda. We excluded 1243 (49.4%) records due to 
missing files, files with missing information/biophys-
ical measurements, type 1 diabetes mellitus or gesta-
tional diabetes mellitus (figure 1). The median age at 
enrolment of the 1275 patients included in this anal-
ysis was 54 (IQR: 44–65) years. Most of the participants 
were female—770 (60.40%), majority lived in an urban 
setting—809 (63.45%) and 544 (42.7%) had attained at 
least primary level education. Of the 1275 participants, 
349 (27%) were obese, 455 (36%) were overweight, 44 
(3.5%) were underweight and 427 (33.5%) had normal 
BMI (table 1).
Factors associated with overweight/obesity
The factors found to be associated with overweight and 
obesity among T2DM patients were female gender, 
age, SES, fruit and vegetable intake, diabetes treatment 
options, neuropathy and hypertension (table 2). In 
general, the risk of being overweight or obese was lower 
in men than in women (OR: 0.45, 95% CI: 0.340 to 0.593, 
p≤0.001). Among the different age categories, the highest 
Figure 1 Study organogram.BMI, body mass index; DM, diabetes mellitus.
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N (%) P value
Sociodemographic characteristics
Gender
Female 770 (60.40) 208 (48.71) 20 (45.45) 277 (60.88) 265 (75.93) <0.001*
Male 505 (39.60) 219 (51.29) 24 (54.55) 178 (39.12) 84 (24.07)
Median age (IQR) (years) 54 (44–65) 55 (44–65) 44.5 (40.5–63) 54 (44–64) 53 (45–62) 0.268
Age group (years)
19–44 326 (25.57) 108 (25 29) 20 (45.45) 120 (26.37) 78 (22.35) 0.003*
45–64 629 (49.33) 195 (45.57) 14 (31.82 224 (49.23) 196 (56.16)
Above 64 320 (25.10) 124 (29.04) 10 (22.73) 111 (24.40) 75 (21.49)
Residence
Rural 138 (10.82) 55 (12.88) 3 (6.82) 53 (11.69) 27 (7.74) 0.294
Peri- urban 328 (25.73) 110 (25.76) 14 (31.82) 115 (25.27) 89 (25.50)
Urban 809 (63.45) 262 (61.36) 27 (61.36) 287 (63.08) 233 (66.76)
Education level
≤Primary education 544 (42.70) 175 (40.98) 18 (40.91) 193 (42.42) 158 (45.27) 0.608
Secondary 460 (36.00) 151 (35.36) 15 (34.09) 165 (36.26) 129 (36.96)
Postsecondary 271 (21.30) 101 (23.63) 11 (25.00) 97 (21.32) 62 (17.77)
Socioeconomic status
Lower 283 (22.20) 125 (29.27) 13 (29.55) 83 (18.25) 62 (17.77) <0.001*
Middle 586 (45.96) 187 (43.79) 18 (40.91) 221 (48.57) 160 (45.85)
Upper 406 (31.84) 115 (26.93) 13 (29.55) 151 (33.19) 127 (36.39)
Life style characteristics
Smoking
No 1137 (89.1) 370 (86.65) 38 (86.36) 408 (89.67) 320 (91.69) 0.136
Yes 139 (10.9) 57 (13.35) 6 (13.64) 47 (10.33) 29 (8.31)
Fruit/vegetable intake
Rarely 462 (38.12) 178 (43.95) 22 (50.00) 154 (35.73) 108 (32.53) 0.007*
Once a week 406 (33.50) 134 (33.09) 9 (20.45) 145 (33.64) 118 (35.54)
Daily 344 (28.38) 93 (22.96) 13 (29.55) 132 (330.63) 106 (31.93)
Alcohol intake
No 909 (71.29) 319 (74.71) 29 (65.91) 316 (69.45) 245 (70.20) 0.260
Yes 366 (28.71) 108 (25.29) 15 (34.09) 139 (30.55) 104 (29.80)
DM treatment characteristics
Life style alone 34 (2.69) 16 (3.79) 1 (2.33) 8 (1.66) 9 (2.62) 0.002*
Monotherapy 292 (23.14) 113 (26.78) 8 (18.60) 98 (21.63) 73 (21.22)
Dual therapy 711 (56.34) 202 (47.87) 24 (55.81) 281 (62.03) 204 (59.30)
Triple therapy 109 (8.64) 38 (39.00) 2 (4.65) 36 (7.95) 33 (9.59)
Combination injection 
therapy
116 (9.19) 53 (12.56) 8 (18.60) 30 (6.62) 25 (7.27)
DM complications and  
comorbidities
Peripheral neuropathy
No 795 (62.35) 293 (68.61) 28 (63.64) 278 (61.10) 196 (56.16) 0.004*
Yes 480 (37.65) 134 (31.39) 16 (36.36) 177 (38.90) 153 (43.84)
Continued
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prevalence of overweight/obesity was between the age of 
45 and 65 years; those age 65 years and more had the 
least risk (OR: 0.52, 95% CI: 0.350 to 0.770, p=0.001). 
Middle and upper SES were associated with increased 
risk of obesity and overweight (OR: 1.83, 95% CI: 1.320 
to 2.550, p≤0.001) and (OR: 2.10, 95% CI: 1.450 to 2.990, 
p<0.001), respectively. Intriguingly, those who reported 
to rarely consuming fruits and vegetables were less likely 
to be overweight or obese than those who had regular 
intake of fruits and vegetables (OR: 0.66, 95% CI: 0.475 to 
0.921, p=0.014). Patients who were on dual therapy were 
more than 2.2 times more likely to be overweight and 
obese (OR: 2.17, 95% CI: 1.024 to 4.604 and p=0.043). 
Patients who had neuropathy complications were 1.4 
times more likely to be overweight and obese (OR: 1.40, 
95% CI: 1.039 to 1.834, p=0.026). Diabetic patients who 
also had hyperte nsion were more than 1.7 times more 
likely to be overweight or obese (OR: 1.70, 95% CI: 1.264 
to 2.293, p<0.001) (table 2).
Discussion
In this study, we observed nearly 65% of patients with 
T2DM were either overweight or obese. The prevalence 
was particularly high among female patients, those with 
middle or higher SES, between 40 and 65 years of age, on 
multiple antidiabetic drugs and those with comorbidity or 
complications.
The prevalence of overweight and obesity among type 
2 diabetes patients in this study was markedly higher than 
the 24.8% found in the general (non- diabetic) population 
in Eastern Uganda in 2013,20 but was consistent with data 
from other settings which showed high levels of overweight 
and obesity among T2DM patients. Indeed, high preva-














N (%) P value
Nephropathy
No 1194 (93.65) 401 (93.91) 42 (95.45) 422 (92.75) 329 (94.27) 0.768
Yes 81 (6.35) 26 (6.09) 2 (4.55) 33 (7.25) 20 (5.73)
Retinopathy
No 1019 (79.92) 349 (81.73) 38 (86.36) 352 (77.36) 280 (80.23) 0.274
Yes 256 (20.08) 78 (18.27) 6 (13.64) 103 (22.64) 69 (19.77)
Macroangiopathy
No 1246 (97.73) 416 (97.42) 43 (97.73) 450 (98.90) 337 (96.56) 0.162
Yes 27 (2.27) 11 (2.58) 1 (2.27) 5 (1.10) 12 (3.44)
Cerebrovascular accident
No 1261 (98.90) 422 (98.83) 44 (100) 451 (99.12) 344 (98.57) 0.784
Yes 14 (1.10) 5 (1.17) 0 (0) 4 (0.88) 5 (8.43)
Hypertension
No 388 (30.40) 160 (37.50) 22 (50.00) 127 (27.90) 79 (22.60) <0.001*
Yes 887 (69.60) 267 (62.50) 22 (50.00) 328 (72.10) 270 (77.40)
Glycaemic control (n=1234)
Hypoglycaemic 18 (1.46) 9 (2.20) 1 (2.38) 4 (0.90) 4 (1.18) 0.509
Optimal glycaemic control 326 (26.42) 103 (25.18) 11 (26.19) 113 (25.51) 99 (29.12)
Uncontrolled glycaemia 890 (72.12) 297 (72.6) 30 (71.43) 326 (73.59) 237 (69.71)
Erectile dysfunction (n=505)
No 396 (78.42) 176 (80.37) 22 (91.69) 131 (73.60) 67 (79.76) 0.150
Yes 109 (21.58) 43 (19.63) 2 (8.33) 47 (26.40) 17 (20.24)
Lost to follow- up 
(≥6 months consecutively)
No 108 (8.5) 23 (5.39) 1 (2.27) 46 (10.11) 38 (10.89) 0.009*
Yes 1167 (91.53) 404 (94.61) 43 (97.73) 409 (89.89) 311 (89.11)
*Statistically significant at level p<0.05.
BMI, body mass index; DM, diabetes mellitus.
Table 1 Continued
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example, in the UK, approximately 86%–90% of patients 
with T2DM had BMI≥25;21 22 in Australia, 53% were obese 
and 32.8% were overweight;23 in Saudi Arabia, 87.5% had 
BMI≥25 with the prevalence being higher among females 
(87.7%) than males (83.1%).24 Although data from 
sub- Saharan Africa are limited, varying rates have been 
observed in Ethiopia (40%),25 Tanzania (85.0%),14 Nigeria 
(27.4%–83%)15 16 and Sudan (64.4%).26 It is likely that with 
the current trends towards urbanisation and globalisation 
and adoption of associated behaviours (eating habits and 
reduced physical activity), the prevalence of overweight and 
obesity in sub- Saharan Africa, including among patients 
with T2DM, will increase sharply27—with a parallel increase 
in complications such as cardiovascular diseases. Unlike in 
high- income countries where overweight and obesity are 
common among individuals with lower SES, in sub- Saharan 
Africa, the prevalence is higher among the educated and 
affluent and higher BMI has a number of positive social 
connotations.28
Table 2 Unadjusted and adjusted logistic regression model of overweight and obesity among type 2 diabetic patients in St. 
Francis Hospital Nsambya
Variable
Unadjusted model Adjusted model
OR 95% CI P value OR 95% CI P value
Sex
Female Ref
Male 1.60 1.092 to 2.4 0.017* 0.45 0.340 to 0.593 <0.001*
Age (years)
19–44 Ref Ref Ref Ref
45–64 1.20 0.879 to 1.569 0.275 0.86 0.620 to 1.190 0.356
65+ 0.81 0.590 to 1.134 0.228 0.52 0.353 to 0.770 0.001*
Lost to follow- up
No Ref Ref Ref Ref
Yes 0.49 0.303 to 0.786 0.003* 0.68 0.400 to 1.150 0.150
Socioeconomic status
Lower Ref Ref Ref Ref
Middle 1.76 1.305 to 2.362 <0.001* 1.83 1.320 to 2.550 <0.001*
Upper 2.10 1.508 to 2.879 <0.001* 2.10 1.452 to 2.994 <0.001*
Smoking status
No Ref Ref Ref Ref
Yes 0.68 0.470 to 0.976 0.037* 0.99 0.643 to 1.490 0.920
Fruit and vegetable intake
Daily Ref Ref Ref Ref
Once a week 0.77 0.558 to 1.053 1.101 0.87 0.619 to 1.227 0.432
Rarely 0.58 0.423 to 0.781 <0.001* 0.66 0.475 to 0.921 0.014*
Treatment of diabetes
Exercise and diet alone Ref Ref Ref Ref
Monotherapy 1.42 0.691 to 2.934 0.338 1.40 0.644 to 3.017 0.43
Dual therapy 2.26 1.120 to 4.560 0.023* 2.17 1.024 to 4.604 0.043*
Triple therapy 1.71 0.776 to 3.763 0.183 1.43 0.613 to 3.334 0.407
Combination injection therapy 0.98 0.448 to 2.130 0.953 0.96 0.414 to 2.204 0.914
Complications of diabetes
Peripheral neuropathy
No Ref Ref Ref Ref
Yes 1.52 1.188 to 1.951 0.001 1.40 1.039 to 1.834 0.026*
Hypertension
No Ref Ref Ref Ref
Yes 1.74 1.352 to 2.237 <0.001* 1.70 1.264 to 2.293 <0.001*
*Indicating significant values based on χ2 value p- value <0.05.
Ref, reference category.; .
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As with other studies in the region, our study showed 
that overweight and obesity among T2DM patients were 
more common among women. The reasons for this are 
not fully understood, but may relate to social drivers as 
well as biological factors.29 Nonetheless, as associations 
with age, education and SES, these findings underscore 
the importance of understanding the local context when 
designing potential interventions to target at risk groups.
Intriguingly, in our study, we found that patients who 
rarely took fruits and vegetables were less likely to be over-
weight or obese compared with those ate fruits and vege-
tables daily. The reasons for this discrepancy are unclear; 
it might relate to unreliability of self- reported data. It is 
also possible that this is a reflection of SES—individuals 
with higher SES are likely to eat more vegetables, but 
are also more likely to be overweight or obese because 
of other dietary habits and/or other behaviours (such as 
physical inactivity). Indeed, most studies have shown that 
for increased fruit and vegetable intake to be successful in 
controlling overweight and obesity, it needs to be combined 
with other weight loss programmes like advice to reduce 
energy intake.30
T2DM patients who were on more than one antidiabetic 
agent were twice more likely to be overweight and obese. 
The majority of these patients were on thiazolinediones 
and sulphonylureas which, together with insulin, cause 
weight gain. This makes it difficult to determine how much 
of the excessive body weight was primary and how much 
was due to the effect of medication. Findings from other 
studies have shown that secretagogues which include sulfo-
nylureas (glyburide, glipizide and glimepiride), insulin and 
thiazolidinediones cause weight gain of 2–3 kg,31 of up to 
1.8 kg32 and 1.5–4 kg,33 34 respectively.
The association between overweight or obese and 
diabetic complications has also been reported in other 
studies, such as the KORA study and the National Health 
and Nutrition Examination Survey III where overweight 
and obesity among diabetes patients were associated with 
diabetic peripheral neuropathy.35 36 Similarly, a number of 
studies have document associations between hypertension 
and overweight and/or obesity among T2DM patients,37–40 
perhaps reflecting clustering of components of the meta-
bolic syndrome.37 41
Study strengths
To our understanding, this study is one of the first studies 
to report on the prevalence and factors associated with 
overweight and obesity among type 2 diabetes patients 
receiving diabetes care in a private not for profit health 
facility in Uganda. Determining the prevalence of over-
weight and obesity among type 2 diabetes patients is 
important as these are directly related to increased 
morbidity and mortality among diabetes patients as 
well as in the general population. The use of patients’ 
routine care data over a 13- year period for this review has 
provided us with a large sample size which would not have 
been feasible otherwise.
Study limitations
Our study findings might have been affected by a selec-
tion bias and thus may not be generalisable to all type 
2 diabetes patients as we have not included those who 
sought care from public non- paying health facilities. As 
with most clinic care records, the quality of data recorded 
is usually less satisfactory for research purposes, and in 
our case, the incomplete and missing data on weight and 
height might have biassed our findings. Additionally, 
these operational programme data were not designed for 
research purposes, thus was not validated, had no quality 
checks done for completeness and plausibility and we 
were only able to look at a limited number of variables 
documented in the patient’s charts. Due to the changes in 
the general economic status in the country, the patients’ 
economic status might have changed over the 13- year 
duration of the study from what it was at registration in 
the clinic. The method used by the health facility to clas-
sify SES and residence were not standardised and could 
have changed over the years.
CONCLUSION
Overweight and obesity were high among T2DM patients 
in this population and may contribute significantly to the 
burden and poor outcomes of T2DM. Female gender, 
middle and higher SES, age between 40 and 60 years, 
being on multiple antidiabetic drugs and having comor-
bidity or complications were associated with overweight 
and obesity. Appropriate control strategies to improve 
nutrition and promote weight loss are urgently needed to 
mitigate this increasing health challenge.
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